On November 22, 2017, Stanley Yarbro filed a preliminary proxy statement soliciting proxies and urged the shareholders of Calmare Therapeutics Incorporated (i) to vote for the election of following 5 persons as directors of the Company: Stanley Yarbro, Vice Admiral Robert Conway, Steve Roehrich, Robert Davis, and Benjamin Large and (ii) to removal without cause of Conrad Peter Brennan, Rustin Howard, and Carl O’Connell as directors of the Company at the 2017 annual shareholders meeting.